 |
|
|
| |
Ongoing analysis of virologic control / functional cure of HBV and HDV infection following
REP 2139-Ca and pegylated interferon alpha-2a therapy in patients with chronic
HBV / HDV co-infection: 3.5-year follow-up results from the REP 301-LTF study
|
| |
| |
AASLD 2019 Nov 8-12 Boston
Michel Bazinet1, Victor Pāntea2, Valentin Cebotarescu2, Lilia Cojuhari2, Pavlina Jimbei3, Adalbert Krawczyk4,5, U. Dittmer5, Andrew Vaillant1
1. Replicor Inc. Montreal, Canada;
2. 2. Department of Infectious Diseases, N. TestemitanuState University of Medicine and Pharmacy, Chisinau, Republic of Moldova;
3. Toma CiorbaInfectious Clinical Hospital, Chisinau, Republic of Moldova;
4. Institute for Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany;
5. Department of Infectious Diseases, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
|
| |
|
|
|
|
|
